Related Experiment Video
Updated: Sep 11, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
[Ambulatory treatment of so-called "essential" arterial hypertension with pindolol. Short-term study]
Abstract:
The results of a study carried out with pindolol (Visken-Sandoz, 5 mg tablets) are reported. The study had the following objectives: 1) to assess the hypotensive effect of the drug in a group of 45 outpatients; 2) to establish effectiveness variations on the basis of the number of daily administrations and doses; 3) to monitor the behaviour of arterial pressure under effort before and after the period of the study. The results obtained show that, for hypertensive patients classifiable in WHO groups 1 and 2, pindolol is effective and recommended unconditionally for out-patient treatment. In most of the patients, two administrations a day are sufficient to maintain pressure values within acceptable limits.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Peripheral Artery Disease III: Interprofessional Care
